Abbott Beats, Raises Outlook - Analyst Blog NASDAQ Abbott Labs, along with partner Biogen ( BIIB ), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis ( RRMS ). Abbott Labs is also working on an intestinal gel for advanced Parkinson's disease ... |
